Short answer
Corvus Pharmaceuticals, Inc. (CRVS) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$18M
- −124.5% YoY · −31.2% QoQ
- EPS (diluted)
- −$0.20
- −53.8% YoY · −33.3% QoQ
Source: XBRL data from the Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 10-Q on SEC EDGAR. USD.
Corvus Pharmaceuticals, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No newly triggered risk factor identified; excerpt contains standard carried-forward risks from the 10-K
- Net loss $31.7 million and accumulated deficit $443.9 million as of June 30, 2026
- Cash, equivalents and marketable securities $215.2 million, funding operations into second quarter 2028
- EU Clinical Trials Regulation fully applies after January 31, 2025, increasing compliance requirements for clinical trials
- Clinical-trial delays or adverse results could postpone approval and commercialization of soquelitinib, ciforadenant and mupadolimab
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Corvus Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.